Zacks Investment ResearchThu, 07 May 2026 15:51:10 GMTSarepta's Q1 Earnings & Sales Beat Estimates, '26 Outlook MaintainedSRPT+3.29%
Seeking AlphaThu, 07 May 2026 03:41:15 GMTSarepta Therapeutics, Inc. (SRPT) Q1 2026 Earnings Call TranscriptSRPT+3.29%
Zacks Investment ResearchWed, 06 May 2026 23:31:28 GMTSarepta Therapeutics (SRPT) Reports Q1 Earnings: What Key Metrics Have to SaySRPT+3.29%
Zacks Investment ResearchWed, 06 May 2026 22:25:30 GMTSarepta Therapeutics (SRPT) Q1 Earnings and Revenues Top EstimatesSRPT+3.29%
Zacks Investment ResearchFri, 27 Mar 2026 16:31:10 GMTWhy Is Sarepta Therapeutics (SRPT) Up 24.2% Since Last Earnings Report?SRPT+3.29%
Zacks Investment ResearchThu, 26 Mar 2026 18:15:33 GMTSRPT Stock Surges on Promising Early Results From siRNA ProgramsSRPT+3.29%
Zacks Investment ResearchThu, 26 Mar 2026 14:01:25 GMTSarepta Therapeutics (SRPT) Soars 35.0%: Is Further Upside Left in the Stock?SRPT+3.29%
Seeking AlphaWed, 25 Mar 2026 21:35:55 GMTSarepta Therapeutics, Inc. (SRPT) Discusses Preliminary Phase I/II Data for SRP-1001 in FSHD1 and SRP-1003 in DM1 TranscriptSRPT+3.29%
24/7 Wall StreetWed, 25 Mar 2026 13:44:47 GMTSarepta Therapeutics Zooms 20% Higher on Promising Clinical Data: Is SRPT Ready for a Bigger Breakout?SRPT+3.29%
Zacks Investment ResearchFri, 20 Mar 2026 15:50:47 GMTSarepta Plans FDA Filings Seeking Full Approval for Two DMD TherapiesSRPT+3.29%
BenzingaThu, 19 Mar 2026 15:51:06 GMTSarepta To Request FDA For Traditional Approvals For Duchenne DrugsSRPT+3.29%
Zacks Investment ResearchTue, 17 Mar 2026 15:35:28 GMTSRPT Stock Up as Enrollment Begins in DMD Gene Therapy Safety StudySRPT+3.29%
Seeking AlphaTue, 03 Mar 2026 22:32:18 GMTSarepta Therapeutics, Inc. (SRPT) Presents at TD Cowen 46th Annual Health Care Conference TranscriptSRPT+3.29%
